Biogen Inc.
SYFOVRE
geographic atrophy secondary to age-related macular degeneration
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for SYFOVRE in geographic atrophy secondary to age-related macular degeneration are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“In November 2025, Apellis presented a post-hoc analysis of its five-year long-term efficacy data from the GALE open-label extension study, showing SYFOVRE delayed GA lesion progression by approximately 1.5 years in patients with nonsubfovea”